ClinicalTrials.Veeva

Menu

Interstitial Fluid in the Development of Cardiovascular Disease

K

Karolinska University Hospital

Status

Completed

Conditions

Type2 Diabetes
Atherosclerosis

Treatments

Other: Collection of interstitial fluid, skin biopsies and blood

Study type

Observational

Funder types

Other

Identifiers

NCT03386097
DiabetesIC2

Details and patient eligibility

About

At a given level of serum cholesterol, patients with T2D have an increased risk of developing atherosclerosis compared with nondiabetic subjects.

In a previous study we showed that the interstitial fluid-to-serum gradient of LDL and VLDL cholesterol is reduced in T2D patients compared with healthy controls. This was not found for HDL cholesterol. However, the cholesterol transporting function of HDL particles from interstitial fluid from patients with T2D were lower than in healthy controls. We hypothesize that that the apo B-containing particles in T2D patients are more susceptible to be retained or consumed in the extravascular space.

We are to study if skin biopsies from T2D patients contain more cholesterol than biopsies from healthy controls. We hypothesize that samples from T2D patients are richer in cholesterol, which could explain why VLDL and LDL cholesterol are lower in relation to their plasma levels in T2D.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Over 18 years.
  • For the T2D study group: Diagnosed with type 2 diabetes.

Exclusion criteria

For subjects with type 2 diabetes:

  • Systemic inflammatory disease that requires active treatment
  • Thyroid disease that requires active treatment
  • Skin disease that requires active treatment and causes significant changes in the area of the skin that is to be investigated
  • Treatment with oral glucocorticoids
  • Levels of SR, TSH, T4 or Hemoglobin in the blood pronouncedly outside the reference range
  • Pregnancy

For healthy controls:

  • Registered disease in the health declaration that requires continuous systemic treatment. Exception to the above: well controlled hypertension in which case the subject should not have treatment with more than one antihypertensive drug, the drug must not be an alpha-blocker or beta-blocker or thiazide diuretic
  • Skin disease that requires active treatment and causes significant changes in the area of the skin that is to be investigated
  • Blood pressure pronouncedly above 140/90
  • Blood test results pronouncedly outside the reference range
  • Pregnancy

Trial design

100 participants in 2 patient groups

Type 2 diabetes patients
Treatment:
Other: Collection of interstitial fluid, skin biopsies and blood
Healthy controls
Treatment:
Other: Collection of interstitial fluid, skin biopsies and blood

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems